MOSH syndrome (Male obesity secondary hypogonadism): Clinical assessment and possible therapeutic approaches

Nutrients

Volumn 10, Issue 4, 2018, Pages

  de Lorenzo, Antonino ^a,b   Noce, Annalisa ^c   Moriconi, Eleonora ^a,d   Rampello, Tiziana ^a   Marrone, Giulia ^a,c   di Daniele, Nicola ^c   Rovella, Valentina ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Casa di Cura Madonna dello Scoglio   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d Nutrition Service   (Italy)

Author keywords

Aromatase activity; Food addiction; Lifestyle change; MOSH syndrome; Testosterone 17 Beta estradiol ratio

Indexed keywords

AROMATASE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLTESTOSTERONE; PROLACTIN; TESTOSTERONE; BIOLOGICAL MARKER;

AGING MALE SYMPTOMS SCALE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY WEIGHT LOSS; BONE MINERALIZATION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EATING DISORDER; FERTILITY; FOOD ADDICTION; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HYPOGONADISM; LIFESTYLE MODIFICATION; LIPID METABOLISM; MALE OBESITY SECONDARY HYPOGONADISM; PHYSICAL ACTIVITY; QUESTIONNAIRE; SEXUAL FUNCTION; SYMPTOM ASSESSMENT; WAIST CIRCUMFERENCE; YALE FOOD ADDICTION SCALE; ADULT; BLOOD; CALORIC RESTRICTION; COMPLICATION; DIET THERAPY; EUNUCHOIDISM; EXERCISE; ITALY; KINESIOTHERAPY; MALE; MIDDLE AGED; NUTRITIONAL STATUS; OBESITY; PATHOPHYSIOLOGY; PILOT STUDY; PROCEDURES; RISK REDUCTION; SYNDROME; TIME FACTOR; TREATMENT OUTCOME;

ADIPOSITY; ADULT; BIOMARKERS; CALORIC RESTRICTION; ESTRADIOL; EUNUCHISM; EXERCISE; EXERCISE THERAPY; HUMANS; MALE; MIDDLE AGED; NUTRITIONAL STATUS; OBESITY; PILOT PROJECTS; RISK REDUCTION BEHAVIOR; ROME; SYNDROME; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 85045413471     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10040474     Document Type: Article

References (48)

1. De Lorenzo, A.; Soldati, L.; Sarlo, F.; Calvani, M.; Di Lorenzo, N.; Di Renzo, L. New obesity classification criteria as a tool for bariatric surgery indication. World J. Gastroenterol. 2016, 22, 681–703.[CrossRef] [PubMed]
2. Di Daniele, N.; Noce, A.; Vidiri, M.F.; Moriconi, E.; Marrone, G.; Annicchiarico-Petruzzelli, M.; D’Urso, G.; Tesauro, M.; Rovella, V.; De Lorenzo, A. Impact of Mediterranean diet on metabolic syndrome, cancer and longevity. Oncotarget 2017, 8, 8947–8979.[CrossRef] [PubMed]
3. NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 2016, 387, 1377–1396.
4. Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; Mullany, E.C.; Biryukov, S.; Abbafati, C.; Abera, S.F., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the global burden of disease study 2013. Lancet 2014, 384, 766–781.[CrossRef]
5. Nieschlag, E.; Hermann, M.; Nieschlag, S. Andrology: Male Reproductive Health and Dysfunction, 3rd ed.; Springer: Berlin/Heidelberg, Germany, 2010.
6. Hall, S.A.; Esche, G.R.; Araujo, A.B.; Travison, T.G.; Clark, R.V.; Williams, R.E.; McKinlay, J.B.: Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J. Clin. Endocrinol. Metab. 2008, 93, 3870–3877.[CrossRef] [PubMed]
7. Gore, A.C.; Chappell, V.A.; Fenton, S.E.; Flaws, J.A.; Nadal, A.; Prins, G.S.; Toppari, J.; Zoeller, R.T. Edc-2: The endocrine society’s second scientific statement on endocrine-disrupting chemicals. Endocr. Rev. 2015, 36, E1–E150.[CrossRef] [PubMed]
8. Mihalca, R.; Fica, S. The impact of obesity on the male reproductive axis. J. Med. Life 2014, 7, 296–300.[PubMed]
9. Skakkebaek, N.E.; Rajpert-De Meyts, E.; Buck Louis, G.M.; Toppari, J.; Andersson, A.M.; Eisenberg, M.L.; Jensen, T.K.; Jorgensen, N.; Swan, S.H.; Sapra, K.J., et al. Male reproductive disorders and fertility trends: Influences of environment and genetic susceptibility. Physiol. Rev. 2016, 96, 55–97.[CrossRef] [PubMed]
10. Canale, M.P.; Manca di Villahermosa, S.; Martino, G.; Rovella, V.; Noce, A.; De Lorenzo, A.; Di Daniele, N. Obesity-related metabolic syndrome: Mechanisms of sympathetic overactivity. Int. J. Endocrinol. 2013, 2013, 865965.[CrossRef] [PubMed]
11. Caprio, M.; Isidori, A.M.; Carta, A.R.; Moretti, C.; Dufau, M.L.; Fabbri, A. Expression of functional leptin receptors in rodent leydig cells. Endocrinology 1999, 140, 4939–4947.[CrossRef] [PubMed]
12. Nieschlag, E.; Behre, H.M.; Bouchard, P.; Corrales, J.J.; Jones, T.H.; Stalla, G.K.; Webb, S.M.; Wu, F.C. Testosterone replacement therapy: Current trends and future directions. Hum. Reprod. Update 2004, 10, 409–419.[CrossRef] [PubMed]
13. Goldstein, D.J.: Beneficial health effects of modest weight loss. Int. J. Obes. Relat. Metab. Disord. 1992, 16, 397–415.[PubMed]
14. Pasanisi, F.; Contaldo, F.; de Simone, G.; Mancini, M. Benefits of sustained moderate weight loss in obesity. Nutr. Metab. Cardiovasc. Dis. 2001, 11, 401–406.[PubMed]
15. Cohen, P.G. The hypogonadal-obesity cycle: Role of aromatase in modulating the testosterone-estradiol shunt—A major factor in the genesis of morbid obesity. Med. Hypotheses 1999, 52, 49–51.[CrossRef] [PubMed]
16. Schulster, M.; Bernie, A.M.; Ramasamy, R. The role of estradiol in male reproductive function. Asian J. Androl. 2016, 18, 435–440.[PubMed]
17. Tremellen, K.: Gut endotoxin leading to a decline in gonadal function (GELDING)—A novel theory for the development of late onset hypogonadism in obese men. Basic Clin. Androl. 2016, 26, 7.[CrossRef] [PubMed]
18. Shang, T.; Zhang, X.; Wang, T.; Sun, B.; Deng, T.; Han, D.: Toll-like receptor-initiated testicular innate immune responses in mouse leydig cells. Endocrinology 2011, 152, 2827–2836.[CrossRef] [PubMed]
19. Dohle, G.R.; Arver, S.; Bettocchi, C.; Jones, T.H.; Kliesch, S. EAU guidelines in male hypogonadism. Eur. Assoc. Urol. 2015, 3, 242–252.
20. Volkow, N.D.; O’Brien, C.P. Issues for DSM-V: Should obesity be included as a brain disorder? Am. J. Psychiatry 2007, 164, 708–710.[CrossRef] [PubMed]
21. Cota, D.; Tschop, M.H.; Horvath, T.L.; Levine, A.S. Cannabinoids, opioids and eating behavior: The molecular face of hedonism? Brain Res. Rev. 2006, 51, 85–107.[CrossRef] [PubMed]
22. Heinemann, L.; Zimmermann, T.; Vermeulen, A.; Thiel, C. A new “aging male’s symptoms” (AMS) rating scale. Aging Male 1999, 2, 105–114.[CrossRef]
23. Gearhardt, A.N.; Corbin, W.R.; Brownell, K.D. Preliminary validation of the yale food addiction scale. Appetite 2009, 52, 430–436.[CrossRef] [PubMed]
24. Dandona, P.; Rosenberg, M.T. A practical guide to male hypogonadism in the primary care setting. Int. J. Clin. Pract. 2010, 64, 682–696.[CrossRef] [PubMed]
25. Bhasin, S.; Woodhouse, L.; Casaburi, R.; Singh, A.B.; Bhasin, D.; Berman, N.; Chen, X.; Yarasheski, K.E.; Magliano, L.; Dzekov, C., et al. Testosterone dose-response relationships in healthy young men. Am. J. Physiol. Endocrinol. Metab. 2001, 281, E1172–E1181.[CrossRef] [PubMed]
26. Lohman, T.; Roche, A.; Martorell, R. Anthropometric Standardization Reference Manual; Human Kinetics Press: Champaing, IL, USA, 1998.
27. Nuttall, F.Q. Body mass index: Obesity, BMI, and health: A critical review. Nutr. Today 2015, 50, 117–128.[CrossRef] [PubMed]
28. Madden, A.M.; Smith, S. Body composition and morphological assessment of nutritional status in adults: A review of anthropometric variables. J. Hum. Nutr. Diet. 2016, 29, 7–25.[CrossRef] [PubMed]
29. De Lorenzo, A.; Bianchi, A.; Maroni, P.; Iannarelli, A.; Di Daniele, N.; Iacopino, L.; Di Renzo, L. Adiposity rather than BMI determines metabolic risk. Int. J. Cardiol. 2013, 166, 111–117.[CrossRef] [PubMed]
30. Heinemann, L.A.; Saad, F.; Zimmermann, T.; Novak, A.; Myon, E.; Badia, X.; Potthoff, P.; T’Sjoen, G.; Pollanen, P.; Goncharow, N.P., et al. The aging males’ symptoms (AMS) scale: Update and compilation of international versions. Health Qual. Life Outcomes 2003, 1, 15.[CrossRef] [PubMed]
31. Innamorati, M.; Imperatori, C.; Manzoni, G.M.; Lamis, D.A.; Castelnuovo, G.; Tamburello, A.; Tamburello, S.; Fabbricatore, M. Psychometric properties of the Italian yale food addiction scale in overweight and obese patients. Eat. Weight Disord. 2015, 20, 119–127.[CrossRef] [PubMed]
32. De Lorenzo, A.; Tagliabue, A.; Andreoli, A.; Testolin, G.; Comelli, M.; Deurenberg, P. Measured and predicted resting metabolic rate in Italian males and females, aged 18–59 y. Eur. J. Clin. Nutr. 2001, 55, 208–214.[CrossRef] [PubMed]
33. Hill, J.O.; Wyatt, H.R.; Peters, J.C. Energy balance and obesity. Circulation 2012, 126, 126–132.[CrossRef] [PubMed]
34. Associazione Medici Diabetologi. Standard Italiani per la Cura del Diabete Mellito; Società Italiana di Diabetologia (SID): Roma, Italy, 2016.
35. Kaur, J. A comprehensive review on metabolic syndrome. Cardiol. Res. Pract. 2014, 2014, 943162.[CrossRef] [PubMed]
36. Donohoe, C.L.; Doyle, S.L.; Reynolds, J.V.: Visceral adiposity, insulin resistance and cancer risk. Diabetol. Metab. Syndr. 2011, 3, 12.[CrossRef] [PubMed]
37. Castro, A.V.; Kolka, C.M.; Kim, S.P.; Bergman, R.N. Obesity, insulin resistance and comorbidities? Mechanisms of association. Arq. Bras. Endocrinol. Metabol. 2014, 58, 600–609.[CrossRef] [PubMed]
38. Toomey, C.M.; McCormack, W.G.; Jakeman, P. The effect of hydration status on the measurement of lean tissue mass by dual-energy X-ray absorptiometry. Eur. J. Appl. Physiol. 2017, 117, 567–574.[CrossRef] [PubMed]
39. Noce, A.; Vidiri, M.F.; Marrone, G.; Moriconi, E.; Bocedi, A.; Capria, A.; Rovella, V.; Ricci, G.; De Lorenzo, A.; Di Daniele, N. Is low-protein diet a possible risk factor of malnutrition in chronic kidney disease patients? Cell Death Discov. 2016, 2, 16026.[CrossRef] [PubMed]
40. Carrelli, A.; Bucovsky, M.; Horst, R.; Cremers, S.; Zhang, C.; Bessler, M.; Schrope, B.; Evanko, J.; Blanco, J.; Silverberg, S.J., et al. Vitamin D storage in adipose tissue of obese and normal weight women. J. Bone Miner. Res. 2017, 32, 237–242.[CrossRef] [PubMed]
41. Annalisa, N.; Alessio, T.; Claudette, T.D.; Erald, V.; Antonino de, L.; Nicola, D.D. Gut microbioma population: An indicator really sensible to any change in age, diet, metabolic syndrome, and life-style. Mediators Inflamm. 2014, 2014, 901308.[CrossRef] [PubMed]
42. Pedersen, B.K. Muscle as a secretory organ. Compr. Physiol. 2013, 3, 1337–1362.[PubMed]
43. Mazur-Bialy, A.I.; Bilski, J.; Pochec, E.; Brzozowski, T. New insight into the direct anti-inflammatory activity of a myokine irisin against proinflammatory activation of adipocytes. Implication for exercise in obesity. J. Physiol. Pharmacol. 2017, 68, 243–251.[PubMed]
44. Jastroch, M.; Oelkrug, R.; Keipert, S. Insights into brown adipose tissue evolution and function from non-model organisms. J. Exp. Biol. 2018, 221.[CrossRef] [PubMed]
45. Armamento-Villareal, R.; Aguirre, L.E.; Qualls, C.; Villareal, D.T. Effect of lifestyle intervention on the hormonal profile of frail, obese older men. J. Nutr. Health Aging 2016, 20, 334–340.[CrossRef] [PubMed]
46. Stanik, S.; Dornfeld, L.P.; Maxwell, M.H.; Viosca, S.P.; Korenman, S.G. The effect of weight loss on reproductive hormones in obese men. J. Clin. Endocrinol. Metab. 1981, 53, 828–832.[CrossRef] [PubMed]
47. Corona, G.; Rastrelli, G.; Monami, M.; Saad, F.; Luconi, M.; Lucchese, M.; Facchiano, E.; Sforza, A.; Forti, G.; Mannucci, E., et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: A systematic review and meta-analysis. Eur. J. Endocrinol. 2013, 168, 829–843.[CrossRef] [PubMed]
48. Woodard, G.; Ahmed, S.; Podelski, V.; Hernandez-Boussard, T.; Presti, J., Jr.; Morton, J.M.: Effect of roux-en-Y gastric bypass on testosterone and prostate-specific antigen. Br. J. Surg. 2012, 99, 693–698.[CrossRef] [PubMed]